AMENDMENT TO THE CLAIMS

Please replace the claims with the claim listing below.

1. (Original) A method for treating a disease caused all or in part by a deficiency in *N*-acetylgalactosamine-4-sulfatase comprising the step of administering a recombinant *N*-acetylgalactosamine-4-sulfatase

2. (Original) The method of claim 1 wherein the disease is a mucopolysaccharidosis.

3. (Original) The method of claim 1 wherein the disease is MPS VI.

4. (Original) The method of claim 1 wherein the disease is Maroteaux-Lamy Syndrome.

5. (Original) The method of claim 1 wherein a patient suffering from the disease demonstrates about 50% or less of a normal *N*-acetylgalactosamine-4-sulfatase activity.

6. (Original) The method of claim 1 wherein at least about 50 Units/kg or at least about 1 mg/kg of a recombinant *N*-acetylgalactosamine-4-sulfatase is administered weekly to a patient suffering from a deficiency thereof.

7. (Original) The method of claim 1 wherein at least about 100 units or 2.0 mg/kg of a recombinant *N*-acetylgalactosamine-4-sulfatase is administered weekly to a patient suffering from a deficiency thereof.

8. (Original) A pharmaceutical composition comprising recombinant *N*-acetylgalactosamine-4-sulfatase and a pharmaceutically acceptable carrier.

9. (Original) The pharmaceutical composition of claim 8 further comprising a sodium chloride solution, a buffer and human albumin.

10. (Original) The pharmaceutical composition of claim 8 wherein the recombinant *N*-acetylgalactosamine-4-sulfatase is present at a concentration of about 1-5 mg/mL or about 50 to about 250 Units per mL.

11. (Original) The pharmaceutical composition of claim 8 wherein the human albumin is present at a concentration of at least about 1 mg/mL.

12. (Original) The pharmaceutical composition of claim 8 wherein the buffer is a sodium phosphate buffer at a concentration of about 10-50 mM.

13. (Original) The pharmaceutical composition of claim 8 wherein the pH of the solution is maintained at about 5.8.

14. (Original) The pharmaceutical composition of claim 8 further comprising polyoxyethylenesorbitan 20 or 80.

15. (Original) The pharmaceutical composition of claim 14, wherein said polyoxyethylenesorbitan concentration is about 0.001% (W/V).

Claims 16-21 (Cancelled)

22. (Original) A cell line transfected with a DNA operable to produce a recombinant N-acetylgalactosamine-4-sulfatase enzyme or a biologically active fragment, analog or mutant thereof; wherein said enzyme is secreted by the cell line or remains in the cell line.

23. (Original) A cell line according to claim 22 wherein the transfected cell is a Chinese Hamster Ovary cell.

24. (Original) A cell line according to claim 23 wherein the transfected cell is a CHO-K1 cell.

25. (Original) A cell line according to claim 24 wherein the transfected cell is a CSL4S-342 cell.

Claims 26-27 (Cancelled)

28. (Original) The recombinant N-acetylgalactosamine-4-sulfatase or biologically active fragment, analog or mutant thereof having a molecular weight of about 55 to 56 kDa.

29. (Original) The recombinant N-acetylgalactosamine-4-sulfatase or biologically active fragment, analog or mutant thereof having a molecular weight of about 64 kDa after glycosylation.

Claims 30-32 (Cancelled)